Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin

Trends in Pharmacological Sciences

Volumn 30, Issue 3, 2009, Pages 129-137

  Kapitulnik, Jaime ^a   Maines, Mahin D ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE PIGMENT; BILIRUBIN; BILIVERDIN REDUCTASE; HEME OXYGENASE 1; I KAPPA B; INSULIN RECEPTOR KINASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXIDOREDUCTASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE C BETA; PROTEIN KINASE C ZETA; SOMATOMEDIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

CELL PROTECTION; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME STRUCTURE; GENE CONTROL; GENE EXPRESSION; GLUCOSE TRANSPORT; HUMAN; NEUROTOXICITY; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; XENOPUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BILE PIGMENTS; BILIRUBIN; CYTOPROTECTION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PROTEIN KINASE C; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 61549122310     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.12.003     Document Type: Review

References (75)

1. Maines M.D. New insights into biliverdin reductase functions: linking heme metabolism to cell signalling. Physiology (Bethesda) 20 (2005) 382-389
2. Hunter T. Protein kinase classification. Methods Enzymol. 200 (1991) 3-37
3. Lerner-Marmarosh N., et al. Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7109-7114
4. Newton A.C. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem. Rev. 101 (2001) 2353-2364
5. Whitby F.G., et al. Crystal structure of a biliverdin IXα reductase enzyme-cofactor complex. J. Mol. Biol. 319 (2002) 1199-1210
6. Ahmad Z., et al. Human biliverdin reductase is a leucine zipper-like DNA-binding protein and functions in transcriptional activation of heme oxygenase-1 by oxidative stress. J. Biol. Chem. 277 (2002) 9226-9232
7. Lerner-Marmarosh N., et al. Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 6870-6875
8. Tudor C., et al. Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expression by haematin. Biochem. J. 413 (2008) 405-416
9. Myers M.G., et al. YMXM motifs and signaling by an insulin receptor substrate 1 molecule without tyrosine phosphorylation sites. Mol. Cell. Biol. 16 (1996) 4147-4155
10. Brandes N., et al. Thiol-based redox switches in eukaryotic proteins. Antioxid. Redox Signal. (2008). http://www.liebertonline.com 10.1089/ARS.2008.2285
11. Kutty R.K., and Maines M.D. Purification and characterization of biliverdin reductase from rat liver. J. Biol. Chem. 256 (1981) 3956-3962
12. Miralem T., et al. Small interference RNA-mediated gene silencing of human biliverdin reductase, but not that of heme oxygenase-1, attenuates arsenite-mediated induction of the oxygenase and increases apoptosis in 293A kidney cells. J. Biol. Chem. 280 (2005) 17084-17092
13. Salim M., et al. Human biliverdin reductase is autophosphorylated, and phosphorylation is required for bilirubin formation. J. Biol. Chem. 276 (2001) 10929-10934
14. Hunter T., and Cooper J.A. Protein-tyrosine kinases. Annu. Rev. Biochem. 54 (1985) 897-930
15. Pawson T., and Scott J.D. Protein phosphorylation in signaling - 50 years and counting. Trends Biochem. Sci. 30 (2005) 286-290
16. Maines M.D., and Gibbs P.E. 30 some years of heme oxygenase: from a 'molecular wrecking ball' to a 'mesmerizing' trigger of cellular events. Biochem. Biophys. Res. Commun. 338 (2005) 568-577
17. Maines M.D. Bile pigments: newcomers to the cell signaling arena. Toxicol. Sci. 71 (2003) 9-10
18. Stocker R. Antioxidant activities of bile pigments. Antioxid. Redox Signal. 6 (2004) 841-849
19. Kapitulnik J. Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol. Pharmacol. 66 (2004) 773-779
20. Ryter S.W., et al. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol. Rev. 86 (2006) 583-650
21. Gibbs P.E., and Maines M.D. Biliverdin inhibits activation of NF-κB: reversal of inhibition by human biliverdin reductase. Int. J. Cancer 121 (2007) 2567-2574
22. Tang L.-M., et al. Exogenous biliverdin ameliorates ischemia-reperfusion injury in small-for-size rat liver grafts. Transplant. Proc. 39 (2007) 1338-1344
23. Taillé C., et al. Heme oxygenase inhibits human airway smooth muscle proliferation via a bilirubin-dependent modulation of ERK1/2 phosphorylation. J. Biol. Chem. 278 (2003) 27160-27168
24. Öllinger R., et al. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 112 (2005) 1030-1039
25. Kapitulnik J., and Gonzalez F.J. Marked endogenous activation of the CYP1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat. Mol. Pharmacol. 43 (1993) 722-725
26. Sinal C.J., and Bend J.R. Aryl hydrocarbon receptor-dependent induction of cyp1a1 by bilirubin in mouse hepatoma Hepa 1c1c7 cells. Mol. Pharmacol. 52 (1997) 590-599
27. Phelan D., et al. Activation of the Ah receptor signal transduction pathway by bilirubin and biliverdin. Arch. Biochem. Biophys. 357 (1998) 155-163
28. Falchuk K.H., et al. A role for biliverdin IXα in dorsal axis development of Xenopus laevis embryos. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 251-256
29. Maines M.D. Biliverdin reductase - a reassessment of its functions in the light of recent discoveries. In: Otterbein L.E., et al. (Ed). Heme Oxygenase (2005), Nova Biomedical Books 287-311
30. Rui L., et al. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277 (2002) 42394-42398
31. Brandman R., et al. Peptides derived from the C2 domain of protein kinase Cε (ε PKC) modulate ε PKC activity and identify potential protein-protein interaction surfaces. J. Biol. Chem. 282 (2007) 4113-4123
32. Gao T., et al. The carboxyl terminus of protein kinase c provides a switch to regulate its interaction with the phosphoinositide-dependent kinase, PDK-1. J. Biol. Chem. 276 (2001) 19588-19596
33. Maines M.D., et al. Human biliverdin reductase, a previously unknown activator of protein kinase CβII. J. Biol. Chem. 282 (2007) 8110-8122
34. Lerner-Marmarosh N., et al. Regulation of TNF-α-activated PKC-ζ signaling by the human biliverdin reductase: identification of activating and inhibitory domains of the reductase. FASEB J. 21 (2007) 3949-3962
35. Ron D., et al. Cloning of an intracellular receptor for protein kinase C: a homolog of the β subunit of G proteins. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 839-843
36. Mochly-Rosen D., et al. p65 fragments, homologous to the C2 region of protein kinase C, bind to the intracellular receptors for protein kinase C. Biochemistry 31 (1992) 8120-8124
37. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 9 (1995) 484-496
38. Stockmann C., and Fandrey J. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin. Exp. Pharmacol. Physiol. 33 (2006) 968-979
39. Igarashi K., and Sun J. The heme-Bach1 pathway in the regulation of oxidative stress response and erythroid differentiation. Antioxid. Redox Signal. 8 (2006) 107-118
40. Kravets A., et al. Biliverdin reductase, a novel regulator for induction of activating transcription factor-2 and heme oxygenase-1. J. Biol. Chem. 279 (2004) 19916-19923
41. Alam J., and Cook J.L. How many transcription factors does it take to turn on the heme oxygenase-1 gene?. Am. J. Respir. Cell Mol. Biol. 36 (2007) 166-174
42. Kim H.P., et al. Caveolae compartmentalization of heme oxygenase-1 in endothelial cells. FASEB J. 18 (2004) 1080-1089
43. Zhang J., et al. BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress. Mol. Cell. Biol. 26 (2006) 7942-7952
44. Pachori A.S., et al. Heme-oxygenase-1-induced protection against hypoxia/reoxygenation is dependent on biliverdin reductase and its interaction with PI3K/Akt pathway. J. Mol. Cell. Cardiol. 43 (2007) 580-592
45. Zeng R., et al. Biliverdin reductase mediates hypoxia-induced EMT via PI3-kinase and Akt. J. Am. Soc. Nephrol. 19 (2008) 380-387
46. Andreadi C.K., et al. Involvement of Nrf2, p38, B-Raf, and nuclear factor-κB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Mol. Pharmacol. 69 (2006) 1033-1040
47. Ryter S.W., et al. Carbon monoxide and bilirubin: potential therapies for pulmonary/vascular injury and disease. Am. J. Respir. Cell Mol. Biol. 36 (2007) 175-182
48. Florczyk U.M., et al. Biliverdin reductase: new features of an old enzyme and its potential therapeutic significance. Pharmacol. Rep. 60 (2008) 38-48
49. Calligaris S.D., et al. Cytotoxicity is predicted by unbound and not total bilirubin concentration. Pediatr. Res. 62 (2007) 576-580
50. Stocker R., et al. Bilirubin is an antioxidant of possible physiological importance. Science 235 (1987) 1043-1046
51. Stocker R., et al. Antioxidant activity of albumin-bound bilirubin. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 5918-5922
52. Barañano D.E., and Snyder S.H. Biliverdin reductase: a major physiologic cytoprotectant. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16093-16098
53. Bulmer A.C., et al. The anti-mutagenic properties of bile pigments. Mutat. Res. 658 (2008) 28-41
54. Schwertner H.A., and Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 198 (2008) 1-11
55. Öllinger R., et al. Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid. Redox Signal. 9 (2007) 2175-2185
56. Loboda A., et al. Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 10 (2008) 1767-1812
57. Bulmer A.C., et al. Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 199 (2008) 390-396
58. Lin J.-P., et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 114 (2006) 1476-1481
59. Shapiro S.M. Bilirubin toxicity in the developing nervous system. Pediatr. Neurol. 29 (2003) 410-421
60. Cesaratto L., et al. Bilirubin-induced cell toxicity involves PTEN activation through an APE1/Ref-1-dependent pathway. J. Mol. Med. 85 (2007) 1099-1112
61. Clark J.F., and Sharp F.R. Bilirubin oxidation products (BOXes) and their role in cerebral vasospasm after subarachnoid hemorrhage. J. Cereb. Blood Flow Metab. 26 (2006) 1223-1233
62. Pyne-Geithman G.J., et al. PKC and Rho in vascular smooth muscle: activation by BOXes and SAH CSF. Front. Biosci. 13 (2008) 1526-1534
63. Pawson T., and Scott J.D. Signaling through scaffold, anchoring, and adaptor proteins. Science 278 (1997) 2075-2080
64. Kim H.J., et al. Heme oxygenase-1 attenuates the cisplatin-induced apoptosis of auditory cells via down-regulation of reactive oxygen species generation. Free Radic. Biol. Med. 40 (2006) 1810-1819
65. Parfenova H., et al. Glutamate induces oxidative stress and apoptosis in cerebral vascular endothelial cells: contributions of HO-1 and HO-2 to cytoprotection. Am. J. Physiol. Cell Physiol. 290 (2006) C1399-C1410
66. Basuroy S., et al. HO-2 provides endogenous protection against oxidative stress and apoptosis caused by TNF-α in cerebral vascular endothelial cells. Am. J. Physiol. Cell Physiol. 291 (2006) C897-C908
67. Kitamura Y., et al. Hyperbilirubinemia protects against focal ischemia in rats. J. Neurosci. Res. 71 (2003) 544-550
68. Deguchi K., et al. Reduction of cerebral infarction in rats by biliverdin associated with amelioration of oxidative stress. Brain Res. 1188 (2008) 1-8
69. De Backer O., and Lefebvre R.A. Investigation of a possible interaction between the heme oxygenase/biliverdin reductase and nitric oxide synthase pathway in murine gastric fundus and jejunum. Eur. J. Pharmacol. 590 (2008) 369-376
70. Lanone S., et al. Bilirubin decreases NOS2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J. 19 (2005) 1890-1892
71. Pflueger A., et al. The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am. J. Physiol. Renal Physiol. 288 (2005) F552-F558
72. Datla S.R., et al. Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase-derived oxidative stress. Hypertension 50 (2007) 636-642
73. Keshavan P., et al. Unconjugated bilirubin inhibits VCAM-1-mediated transendothelial leukocyte migration. J. Immunol. 174 (2005) 3709-3718
74. Wang W.W., et al. Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. Hepatology 40 (2004) 424-433
75. Lindenblatt N., et al. Vascular heme oxygenase-1 induction suppresses microvascular thrombus formation in vivo. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 601-606